Related references
Note: Only part of the references are listed.ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
Naoko Okura et al.
CLINICAL CANCER RESEARCH (2020)
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status
Koji Fukuda et al.
CANCER RESEARCH (2019)
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden
Go Makimoto et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
Khyati N. Shah et al.
NATURE MEDICINE (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer
Ryohei Katayama
CANCER SCIENCE (2018)
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Rajeswara Rao Arasada et al.
NATURE COMMUNICATIONS (2018)
Cancer Statistics for Hispanics/Latinos, 2018
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al.
LANCET ONCOLOGY (2018)
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer
Kenichi Suda et al.
LUNG CANCER (2016)
A genetic cell context-dependent role for ZEB1 in lung cancer
Ting Zhang et al.
NATURE COMMUNICATIONS (2016)
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Michael Ramirez et al.
NATURE COMMUNICATIONS (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1
Claudia Voena et al.
ONCOTARGET (2016)
A HSP60-targeting peptide for cell apoptosis imaging
S. Yang et al.
ONCOGENESIS (2016)
Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells
Xuyuan Dong et al.
NEOPLASIA (2016)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Molecular Pathways: HER3 Targeted Therapy
Kinisha Gala et al.
CLINICAL CANCER RESEARCH (2014)
Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies
Tianhong Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Comprehensive Comparative Analysis of the Histomorphological Features of ALK-Rearranged Lung Adenocarcinoma Based on Driver Oncogene Mutations: Frequent Expression of Epithelial-Mesenchymal Transition Markers than Other Genotype
Hyojin Kim et al.
PLOS ONE (2013)
EMT and MET in Metastasis: Where Are the Cancer Stem Cells?
Thomas Brabletz
CANCER CELL (2012)
Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer
Junko Tanizaki et al.
CLINICAL CANCER RESEARCH (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
Seiji Yano et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Mechanism of the Mesenchymal-Epithelial Transition and Its Relationship with Metastatic Tumor Formation
Dianbo Yao et al.
MOLECULAR CANCER RESEARCH (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery et al.
CELL (2009)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells
X-D Zhou et al.
CELL DEATH AND DIFFERENTIATION (2008)
E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas
Alan Wells et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi P. Koivunen et al.
CLINICAL CANCER RESEARCH (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy
M Sugaya et al.
CHEST (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
KEGG: Kyoto Encyclopedia of Genes and Genomes
M Kanehisa et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
